Sesen Bio Inc

Sesen Bio — Carisma Therapeutics — Technical Presentation (April 2024)

9 slides from Sesen Bio's technical presentation, Apr 10, 2024

  1. Slide 1: CT-0508 Study Monotherapy Patient Demographics (n=14)

    1 CT - 0508 Study 101 Monotherapy Patient Demographics (n=14) Heavily pre - treated pts with HER2 2+/3+ solid tumors Summary of Participant and Tumor Characteristics Characteristic N = 14 Characteristic N = 14 Median age (range), years 58 (45, 81) Tumor Type, n (%) Breast Cancer Esophageal Cancer Sa

  2. Slide 2: 40.7% of all target lesions had reduced in size on at least 1 scan

    2 4/9/2024 40.7% of all target lesions had reduced in size on at least 1 scan Anatomic Location Frequency of tumor lesions that reduced on treatment on at least 1 scan Breast 1/1 (100%) Liver 4/5 (80%) Lung 1/7 (14.3%) Lymph Node 4/8 (50%) Other 1/4 (25%) Skin/Subcutaneous 0/2 (0%) All Lesions 11/27

  3. Slide 3: CT-0508/Pembro Sub-study: Regimen Level 1 Demographics

    3 CT - 0508/ Pembro Sub - study: Regimen Level 1 Demographics Patient Demographics were consistent with Group 1 and Group 2 Summary of Participant and Tumor Characteristics Characteristic N = 3 Characteristic N = 3 Median age (range), years 62 (50, 73) Tumor Type, n (%) Breast Cancer Esophageal Canc

  4. Slide 4: Well Tolerated, No Dose Limiting Toxicities, Similar Safety Profile to CT-0508 Monotherapy

    4 CT - 0508/ Pembro Sub - study: Well Tolerated, No Dose Limiting Toxicities, Similar Safety Profile to CT - 0508 Monotherapy CT - 0508 Monotherapy Group 1: Fractionated Dosing CT - 0508 Monotherapy Group 2: Bolus Dosing CT - 0508 + Pembrolizumab Regimen 1 Patients Treated N=9 (%) N=5 (%) N=3 (%) 1

  5. Slide 5: CT-0508/Pembro Sub-study: Regimen Level (n=3) Summary

    5 CT - 0508/ Pembro Sub - study : Regimen Level 1 (n=3) Summary First two patients received corticosteroids prior to pembrolizumab Patient Steroids Given Prior to Pembro Best Overall Response Disease HER2 Status Additional Treatment Details Patient 1 Yes PD Stage IV Breast Cancer HER2 2+ • Treated w

  6. Slide 6: Patient Case Study Patient #3: HER2+ Esophageal Adenocarcinoma w/ 6 prior lines of therapy

    6 CT - 0508/ Pembro Sub - study: Patient Case Study Patient #3: HER2+ Esophageal Adenocarcinoma w/ 6 prior lines of therapy and refractory to Enhertu Patient 3 - Prior Line Prior Therapy Start Time End Time Best Overall Response 1 Neoadjuvant carboplatin/paclitaxel Feb 2019 April 2019 CR 2 Adjuvant

  7. Slide 7: Patient Case Study Patient #3: 46% reduction in target lesions

    7 CT - 0508/ Pembro Sub - study: Patient Case Study Patient #3: 46% reduction in 1 of 2 target lesions Paratracheal LN Target Lesion: 46% reduction by week 13 Baseline Week 8 Week 13 Dosing • Patient received 3.10E+ 09 cells • Patient missed the 2nd cycle of pembrolizumab Tumor assessments • Paratra

  8. Slide 8: Pt had high baseline peripheral CD8 T cell exhaustion

    8 CT - 0508/ Pembro Sub - study: Pt 3 had high baseline peripheral CD8 T cell exhaustion

  9. Slide 9: Individual Case Study Patient 3: Greatest increase in peripheral blood T cell clonality

    9 CT - 0508/ Pembro Sub - study: Individual Case Study Patient 3: Greatest increase in peripheral blood T cell clonality seen to - date across all 17 patients treated with CT - 0508 Increased T cell clonality in the peripheral blood T cell clonality (Fold change over screening) Monotherapy Pt #3 - S

Carisma Therapeutics — Technical Presentation (April 2024) on 6ix